Bunionectomy Study for Postoperative Analgesia (EPOCH 1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03295721 |
Recruitment Status :
Completed
First Posted : September 28, 2017
Results First Posted : October 27, 2021
Last Update Posted : October 27, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Pain | Drug: HTX-011 Drug: Saline Placebo Drug: Bupivacaine HCl Device: Luer-lock applicator Device: Vial access device | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 412 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy |
Actual Study Start Date : | October 24, 2017 |
Actual Primary Completion Date : | January 8, 2018 |
Actual Study Completion Date : | March 13, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment Group 1: HTX-011
HTX 011 (bupivacaine/meloxicam)
|
Drug: HTX-011
HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation Device: Luer-lock applicator Applicator for instillation Device: Vial access device Device for withdrawal of drug product |
Placebo Comparator: Treatment Group 2: Saline Placebo
Saline placebo
|
Drug: Saline Placebo
Saline placebo by instillation Device: Luer-lock applicator Applicator for instillation |
Active Comparator: Treatment Group 3: Bupivacaine HCI
Bupivacaine HCl
|
Drug: Bupivacaine HCl
Bupivacaine HCl without epinephrine, 50 mg by injection |
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale of Pain Intensity Scores With Activity (NRS-A; Windowed Worst Observation Carried Forward) for HTX-011 Compared With Saline Placebo. [ Time Frame: 72 hours ]Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A), seated with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing).
- Mean AUC of the NRS-A Pain Intensity Scores (Windowed Worst Observation Carried Forward) for HTX 011 Compared With Bupivacaine HCl. [ Time Frame: 72 hours ]Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A) seated with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing).
- Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo. [ Time Frame: 72 hours ]
- Percentage of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl. [ Time Frame: 72 hours ]
- Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl. [ Time Frame: 72 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Is scheduled to undergo a primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia.
- Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
Exclusion Criteria:
- Has had a contralateral foot bunionectomy in the past 3 months.
- Has a planned concurrent surgical procedure (eg, bilateral bunionectomy or collateral procedures on the surgical foot).
- Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
- Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
- Has taken any NSAIDs within at least 10 days prior to the scheduled surgery.
- Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
- Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).
- Has uncontrolled anxiety, psychiatric, or neurological disorder.
- Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
- Has undergone 3 or more surgeries within 12 months.
- Has a body mass index (BMI) >39 kg/m2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03295721
United States, Alabama | |
Springhill Medical Center | |
Mobile, Alabama, United States, 36608 | |
United States, Arizona | |
Orthopaedic Specialists of North America, PLLC | |
Mesa, Arizona, United States, 85206 | |
Arizona Research Center | |
Phoenix, Arizona, United States, 85059 | |
United States, California | |
Anaheim Clinical Trials, LLC | |
Anaheim, California, United States, 92801 | |
Trovare Clinical Research, Inc. | |
Bakersfield, California, United States, 93301 | |
Alliance Research Centers | |
Laguna Hills, California, United States, 92653 | |
United States, Maryland | |
Chesapeake Research Group, LLC | |
Pasadena, Maryland, United States, 21122 | |
United States, Texas | |
Optimal Research , LLC | |
Austin, Texas, United States, 78705 | |
Hermann Drive Surgical Hospital | |
Houston, Texas, United States, 77004 | |
Westside Surgical Hospital | |
Houston, Texas, United States, 77027 | |
Futuro Clinical Trials, LLC | |
McAllen, Texas, United States, 78501 | |
Plano Surgical Hospital | |
Plano, Texas, United States, 75093 | |
Endeavor Clinical Trials | |
San Antonio, Texas, United States, 78229 | |
United States, Utah | |
EPIC Medical Research, LLC | |
Murray, Utah, United States, 84123 | |
Jean Brown Research | |
Salt Lake City, Utah, United States, 84124 |
Documents provided by Heron Therapeutics:
Responsible Party: | Heron Therapeutics |
ClinicalTrials.gov Identifier: | NCT03295721 |
Other Study ID Numbers: |
HTX-011-301 |
First Posted: | September 28, 2017 Key Record Dates |
Results First Posted: | October 27, 2021 |
Last Update Posted: | October 27, 2021 |
Last Verified: | September 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
bunion bunionectomy bunion surgery postoperative pain |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Bupivacaine |
Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |